Medicare Enrolled

Dr. Daniel Desimone, MD

Internal Medicine · Crestwood, IL
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
13755 CICERO AVE, Crestwood, IL 60418
7089727642
In practice since 2005 (20 years)
NPI: 1447246822 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Desimone from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Desimone? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Desimone

Dr. Daniel Desimone is an internal medicine specialist in Crestwood, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Desimone performed 53,517 Medicare services across 332 unique beneficiaries.

Between the years covered by Open Payments, Dr. Desimone received a total of $1,054 from 22 pharmaceutical and/or device companies across 65 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Desimone is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 0% volume in IL $1,054 industry payments

Medicare Practice Summary

Medicare Utilization ↗
53,517
Medicare services
Top 0% in IL for internal medicine
332
Unique beneficiaries
$2
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,676 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Daptomycin antibiotic injection 45,200 $0 $1
Dalbavancin injection, 5 mg
An injection of the antibiotic dalbavancin, administered in a 5 mg dose.
7,000 $12 $31
Ceftriaxone antibiotic injection
This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered.
504 $0 $17
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
313 $53 $225
Ertapenem sodium injection, 500 mg
An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg.
296 $11 $105
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
96 $142 $402
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
56 $24 $100
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
52 $8 $25
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
99.0% medium
0.3% routine

Industry Payment Transparency

Open Payments through 2022 ↗
$1,054
Total received (2019-2022)
Avg $263/year across 4 years
Top 31% in IL for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
22
Companies
65
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,054 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2022
$406
2021
$382
2020
$211
2019
$55

Payments by company (2022)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$95
Lilly USA, LLC
$62
Novartis Pharmaceuticals Corporation
$55
Biohaven Pharmaceutical Holding Company Ltd.
$30
GlaxoSmithKline, LLC.
$30
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$29
ABBVIE INC.
$26
Amarin Pharma Inc.
$20
PFIZER INC.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Amgen Inc.
$19
Top 3 companies account for 52.2% of 2022 payments
All-time payments by company (2019-2022) ›
Novo Nordisk Inc
$138
AstraZeneca Pharmaceuticals LP
$106
Lilly USA, LLC
$105
Amarin Pharma Inc.
$77
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$69
Janssen Pharmaceuticals, Inc
$68
PFIZER INC.
$66
Novartis Pharmaceuticals Corporation
$55
AbbVie Inc.
$50
Eisai Inc.
$38
SANOFI-AVENTIS U.S. LLC
$37
Bayer HealthCare Pharmaceuticals Inc.
$32
Biohaven Pharmaceutical Holding Company Ltd.
$30
GlaxoSmithKline, LLC.
$30
ABBVIE INC.
$26
Medtronic, Inc.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
E.R. Squibb & Sons, L.L.C.
$19
Amgen Inc.
$19
VIVUS, Inc.
$18
Allergan, Inc.
$17
Abbott Laboratories
$14
Top 3 companies account for 33.1% of all-time payments
Associated products mentioned in payments ›
BREZTRI · BYDUREON · COLOGUARD DNA CAPTURE REAGENTS · CREON · Dayvigo · ELIQUIS · ENTRESTO · FreeStyle Libre 2 · Kerendia · LEQVIO · LINZESS · MOUNJARO · Minimed 770G System · NUCALA · NURTEC ODT · Ozempic · PANCREAZE · PREVNAR 13 · RYBELSUS · Repatha · Saxenda · TOUJEO · TRELEGY ELLIPTA · TRULICITY · Tresiba · UBRELVY · Vascepa · XARELTO · XIFAXAN
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an internal medicine specialist in Crestwood?
Compare internal medicine physicians in the Crestwood area by procedure volume, costs, and industry payment transparency.
Browse internal medicine physicians nearby

Geographic Context

Internal medicine physicians within 10 mi
5,058
Per 100K population
97.5
County median income
$81,797
Nearest hospital
PALOS COMMUNITY HOSPITAL
2.8 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2022
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Desimone is a mixed practice specialist, with above-average Medicare volume (top 0% in IL), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Desimone experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Desimone performed 45,200 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Desimone receive payments from pharmaceutical companies?
Yes. Dr. Desimone received a total of $1,054 from 22 companies across 65 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Desimone's costs compare to other internal medicine physicians in Crestwood?
Dr. Desimone's average Medicare payment per service is $2. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Desimone) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →